Study wrapper · #234
An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.
Editor's note
An anti-doping method paper notable for simplifying sample preparation. The researchers validated a urine assay for GHRH analogues, sermorelin/CJC-1293, a sermorelin metabolite, CJC-1295, and tesamorelin, that skips labour-intensive antibody-based purification, relying only on ultrafiltration before nano-liquid-chromatography mass spectrometry, yet still reaching very low detection limits (5-25 pg/mL). A practically useful secondary finding: sermorelin and its metabolite degrade rapidly above 4C and below pH 7, underscoring how sample handling affects results, and, incidentally, how chemically fragile these peptides are. As with the other detection studies, the GHRH analogues appear only as analytes; there is no efficacy, dosing, or safety information about Tesamorelin, Sermorelin, or CJC-1295 here. The relevant context is simply that these compounds are banned in sport and detectable. This is analytical validation, not clinical evidence.
Plain-language abstract
This study describes a simpler laboratory method for detecting banned growth-hormone-releasing peptides in urine, not a study of their effects. Existing methods often use antibodies to pull the peptides out of the sample, which is slow and costly. Instead, the researchers used only ultrafiltration, a filtering step that concentrates the sample, before analysing it with a sensitive mass-spectrometry technique. Even without antibodies, the method detected the target peptides (including sermorelin, CJC-1295, and tesamorelin, plus a sermorelin breakdown product) at extremely low levels, between 5 and 25 trillionths of a gram per millilitre, and it held up well across hundreds of sample injections. The researchers also found that sermorelin and its breakdown product degrade quickly if urine is stored warmer than 4C or at an acidic pH, highlighting the need for careful sample handling. The authors suggested the approach could be extended to other emerging peptide drugs. The study only addresses detection; it does not test whether these peptides work or are safe.